Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility

International Journal of Cancer

Volumn 114, Issue 3, 2005, Pages 394-399

  Lipoldová, Marie ^a   Havelková, Helena ^a   Badalová, Jana ^a   Demant, Peter ^b  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Interleukin 2; Interleukin 4; Lung cancer susceptibility; Lymphocyte activation; Modifiers

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 4; MITOGENIC AGENT;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CANCER SUSCEPTIBILITY; CINDA3 GENE; CINDA4 GENE; CINDA5 GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE; GENE CLUSTER; GENE CONTROL; GENE LOCATION; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HYBRID GENE; IMMUNE RESPONSE; IMMUNOREACTIVITY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE FUNCTION; MALE; MARIF1 GENE; MARIF2 GENE; MOUSE; MULTIGENE FAMILY; NONHUMAN; OCB 9 GENE; PGIA12 GENE; PGIA4 GENE; PGIA7 GENE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS MAPPING; SLUC1 GENE; SLUC20 GENE; SLUC4 GENE; SLUC6 GENE;

ANIMALS; AUTOIMMUNITY; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME; GENOTYPE; INFLAMMATION; LUNG NEOPLASMS; LYMPHOCYTES; MACROPHAGES; MALE; MICE; QUANTITATIVE TRAIT LOCI;

EID: 14044278147     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20731     Document Type: Article

References (34)

1. Havelková H, Kosařová M, Krulová M, Demant P, Lipoldová M. T-cell proliferative response is controlled by loci Tria4 and Tria5 on mouse chromosomes 7 and 9. Mamm Genome 1999;10:670-4.
2. Kosařová M, Havelková H, Krulová M, Demant P, Lipoldová M. The production of two Th2 cytokines, interleukin 4 and interleukin 10 is controlled independently by a locus Cypr1 and loci Cypr2 and Cypr3, respectively. Immunogenetics 1999;49:134-41.
3. Krulová M, Havelková H, Kosařová M, Holáň V, Hart AAM, Demant P, Lipoldová M. IL-2-induced proliferative response is controlled by loci Cinda1 and Cinda2 on mouse chromosomes 11 and 12: a distinct control of the response induced by different IL-2 concentrations. Genomics 1997;42:11-5.
4. Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3:269-79.
5. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998;70:1-81.
6. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38.
7. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 2003;105:512-9.
8. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol 1999;163:1923-8.
9. Allison JP. CD28-B7 interaction in T-cell activation. Curr Opin Immunol 1994;6:414-9.
10. Lai SY, Molden J, Liu KD, Puck JM, White MD, Goldsmith MA. Interleukin-4-specific signal transduction events are driven by homotypic interactions of the interleukin-4 receptor α subunit. EMBO J 1996;15:4506-14.
11. Ellery JM, Nicholls PJ. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Reviews 2002;13:27-40.
12. Demant P, Hart AAM. Recombinant congenic strains: a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 1986;24:416-22.
13. Demant P, Lipoldová M, Svobodová M. Resistance to Leishmania major in mice. Science 1996;274:1392-3.
14. Lipoldová M, Svobodová M, Krulová M, Havelková H, Badalová J, Nohýnková E, Holáň V, Hart AAM, Volf P, Demant P. Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes. Genes Immun 2000;1:200-6.
15. Stassen APM, Groot PC, Eppig JT, Demant P. Genetic composition of the recombinant congenic strains. Mamm Genome 1996;7:55-8.
16. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988;18:97-104.
17. Lipoldová M, Kosařová M, Zajícová A, Holáň V, Hart AAM, Krulová M, Demant P. Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains. Immunogenetics 1995;41:301-11.
18. Havelková H, Badalová J, Demant P, Lipoldová M. A new type of genetic regulation of allogeneic response: a novel locus on mouse chromosome 4, Alan2 controls MLC reactivity to three different alloantigens - C57BL/10, BALB/c and CBA. Genes Immun 2000;1:483-7.
19. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage reports. Nat Genet 1995;11:241-9.
20. Fijneman RJA, de Vries SS, Jansen RC, Demant P. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 1996;14:465-7.
21. Tripodis N, Hart AA, Fijneman RJA, Demant P. Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 2001;93:1484-91.
22. Fijneman RJA, Jansen RC, van der Valk MA, Demant P. High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14. Cancer Res 1998;58:4794-8.
23. Moen CJA, Groot PC, Hart AAM, Snoek M, Demant P. Fine mapping of colon tumor susceptibility (Scc) genes in the mouse, different from the genes known to be somatically mutated in colon cancer. Proc Natl Acad Sci USA 1996;93:1082-6.
24. Calland RE, Gearing AJH, eds. IL-2: the Cytokine facts book. London: Academic Press, 1994. 42.
25. Fijneman RJA, Demant P. A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4. Cancer Res 1995;14:3179-82.
26. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995;81:957-66.
27. Cormier RT, Hong KT, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997;17:88-91.
28. 2. Trends Pharmacol Sci 1999;20:162-70.
29. Fuentes L, Hernandez M, Nieto ML, Sanchez Crespo M. Biological effects of group IIA phospholipase A2. FEBS Lett 2002;531:7-11.
30. Otto JM, Cs-Szabo G, Gallagher J, Velins S, Mikecz, K, Buzas EI, Enders JT, Li Y, Olsen BR, Giant TT. Identification of multiple loci linked to inflammation and antibody production by a genome scan of a murine model of rheumatoid arthritis. Arthrit Rheumat 1999;42:2524-31.
31. Essner R, Huynh Y, Nguyen T, Morton DL, Hoon DSB. Functional interleukin 4 receptor and interleukin 2 receptor common (gamma)-chain on human non-small cell lung cancers: novel targets for immune therapy. J Thorac Cardiovasc Surg 2000;119:10-20.
32. Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husein SR, Puri RK. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res 2002;8:3503-11.
33. Profita M, Vignola AM, Sala A, Mirabella A, Siena L, Pace E, Folco G, Bonsignore B. Interleukin-4 enhances 15-lipoxygenase activity and incorporation of 15(S)-HETE into cellular phospholipids in cultured pulmonary epithelial cells. Am J Respir Cell Mol Biol 1999;20:61-8.
34. Fijneman RJA, Vos M, Berkhof J, Demant P, Kraal G. Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, Marif1, Marif2, and Marif3. Cancer Res 2004;64:3458-64.